ID: ALA149808

Max Phase: Preclinical

Molecular Formula: C9H10N2

Molecular Weight: 146.19

Molecule Type: Small molecule

Representations

Canonical SMILES:  CNCC#Cc1cccnc1

Standard InChI:  InChI=1S/C9H10N2/c1-10-6-2-4-9-5-3-7-11-8-9/h3,5,7-8,10H,6H2,1H3

Standard InChI Key:  NTEDXDYFBMNKGE-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 146.19

Molecular Weight (Monoisotopic): 146.0844

AlogP: 0.65

#Rotatable Bonds: 1

Polar Surface Area: 24.92

Molecular Species: BASE

HBA: 2

HBD: 1

#RO5 Violations: 0

HBA (Lipinski): 2

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 0

CX Acidic pKa:

CX Basic pKa: 8.57

CX LogP: 0.79

CX LogD: -0.40

Aromatic Rings: 1

Heavy Atoms: 11

QED Weighted: 0.59

Np Likeness Score: -0.98

References

1. Dogruer D, Lee M, Dukat M, Damaj MI, Martin BR, Glennon RA..  (2004)  3-(4-Aminobutyn-1-yl)pyridines: binding at alpha 4 beta 2 nicotinic cholinergic receptors.,  14  (2): [PMID:14698195] [10.1016/j.bmcl.2003.10.033]

2. Denton TT, Zhang X, Cashman JR..  (2005)  5-substituted, 6-substituted, and unsubstituted 3-heteroaromatic pyridine analogues of nicotine as selective inhibitors of cytochrome P-450 2A6.,  48  (1): [PMID:15634016] [10.1021/jm049696n]

3. Yano JK, Denton TT, Cerny MA, Zhang X, Johnson EF, Cashman JR..  (2006)  Synthetic inhibitors of cytochrome P-450 2A6: inhibitory activity, difference spectra, mechanism of inhibition, and protein cocrystallization.,  49  (24): [PMID:17125252] [10.1021/jm060519r]

4.  (2013)  Synthetic compounds and derivatives as modulators of smoking or nicotine ingestion and lung cancer, 

5.  (2013)  Synthetic compounds and derivatives as modulators of smoking or nicotine ingestion and lung cancer, 

Source

Source(3):

• Scientific Literature
• BindingDB Database
• Patent Bioactivity Data